This inventor holds 3 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Oryzon Genomics S.a.. Active years: 2013-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Barcelona, ES (2013 - 2015)
- Bercelona, ES (2017)
Company Filing History:
Years Active: 2013-2017
Title: Nathalie Guibourt: Innovator in Viral Infection and Cancer Treatment
Introduction: Nathalie Guibourt, a prominent inventor based in Barcelona, Spain, has made significant strides in the field of pharmaceuticals through her groundbreaking inventions. With a total of three patents to her name, her work primarily focuses on developing potent inhibitors for treating viral infections and cancer.
Latest Patents: Nathalie's latest patents include the development of potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use. This innovation relates to the application of these inhibitors in treating or preventing viral infections, showcasing her commitment to addressing critical health challenges. Additionally, she has contributed to the field with her patent on phenylcyclopropylamine derivatives, which are promising new pharmaceutical compositions. These compounds hold the potential for treating and preventing cancer as well as neurodegenerative diseases or disorders, underscoring the versatility and importance of her work.
Career Highlights: Nathalie Guibourt is currently affiliated with Oryzon Genomics, S.A., where she continues her research and development efforts. Her role at the company places her at the forefront of innovative therapeutic solutions aimed at significantly improving patient outcomes in various medical fields.
Collaborations: In her professional endeavors, Nathalie collaborates with Alberto Ortega Munoz, highlighting the importance of teamwork in driving pharmaceutical innovation. Their combined expertise fosters a collaborative environment essential for the advancement of their shared goals in healthcare.
Conclusion: Nathalie Guibourt’s contributions to the advancement of viral infection and cancer therapies through her patented inventions solidify her status as a leading innovator in the pharmaceutical industry. Her dedication to improving health outcomes through science and innovation is commendable, and her work will undoubtedly continue to inspire future research and development in these critical areas.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile